Delta Med S.p.A.

Delta Med S. p. A. specializes in the development and provision of innovative medical devices focusing on diagnostic and therapeutic solutions aimed at enhancing patient care in healthcare settings.

Founded in 1993, Delta Med S. p. A. operates in Italy and engages in providing medical solutions through innovative technology.

The company was fully acquired in October 2021 by White Bridge Investments and its management from Augens Capital and DB Private Equity, with Augens Capital reinvesting in the company. Mark D is the founder, who has a history of involvement in the medical device industry. Delta Med has engaged in 2 deals, with the most recent occurring on 11 October 2021, during which they raised EUR 19. 50 mn in a Secondary Buyout funding round, amounting to the total amount raised of EUR 19.

50 mn. Delta Med specializes in providing innovative medical solutions with a focus on advanced diagnostic and therapeutic equipment. Their core offerings include a range of medical devices designed for use in hospitals and clinics, which facilitate improved patient care and enhance treatment outcomes. The company’s primary products address critical areas such as imaging technologies and surgical instruments, developed to solve complex medical challenges faced by healthcare professionals.

Delta Med's client base includes hospitals, outpatient facilities, and medical research institutions across North America and Europe, particularly in Germany, France, and the United States. These products are released to meet growing demands in the healthcare sector, ensuring they are equipped with the latest technology to support both clinicians and patients effectively. Delta Med generates revenue through a structured model primarily based on direct sales and long-term partnerships with healthcare providers. Their transactions typically involve B2B engagements where hospitals and clinics acquire equipment through one-time purchases or leasing arrangements.

Additionally, Delta Med may establish service agreements that include maintenance and support for their medical devices, ensuring clients receive ongoing assistance. In 2023, Delta Med reported a revenue of EUR 24,229,583 and an EBITDA of EUR 989,090. 2. Pricing structures for their flagship products vary based on specifications and included services, tailored to meet the specific needs of each client.

Following the recent acquisition, Delta Med plans to utilize the new funding to support its future growth trajectory and develop a platform aimed at further aggregation and consolidation in the medical devices industry, specifically within Italy and broader Europe. The company is focused on designing and launching new products to enhance its offerings in the coming years. As part of their strategic growth plan, Delta Med intends to expand its market presence into new geographic regions, targeting additional opportunities in Europe. The specifics on release dates for new products or market entry strategies will continue to evolve as they adapt to industry demands.